163
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Effect of pregabalin on fear-based conditioned avoidance learning and spatial learning in a mouse model of scopolamine-induced amnesia

, , &
Pages 181-190 | Received 22 Sep 2016, Accepted 03 Dec 2016, Published online: 08 Jan 2017

References

  • Baldwin DS, den Boer JA, Lyndon G, et al. (2015). Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature. J Psychopharmacol 29:1047–60.
  • Bialuk I, Dobosz K, Potrzebowski B, Winnicka MM. (2014). CP55,940 attenuates spatial memory retrieval in mice. Pharmacol Rep 66:931–6.
  • Brandt C, Mula M. (2016). Anxiety disorders in people with epilepsy. Epilepsy Behav 59:87–91.
  • Chavant F, Favrelière S, Lafay-Chebassier C, et al. (2011). Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol 72:898–904.
  • Dadsetan S, Balzano T, Forteza J, et al. (2016). Reducing peripheral inflammation with infliximab reduces neuroinflammation and improves cognition in rats with hepatic encephalopathy. Front Mol Neurosci 9:106.
  • D’Hooge R, De Deyn PP. (2001). Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 36:60–90.
  • Flood JF, Cherkin A. (1986). Scopolamine effects on memory retention in mice: a model of dementia? Behav Neural Biol 45:169–84.
  • Frampton JE. (2014). Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs 28:835–54.
  • Helmstaedter C, Witt JA. (2008). The effects of levetiracetam on cognition: a non-interventional surveillance study. Epilepsy Behav 13:642–9.
  • Hindmarch I, Trick L, Ridout F. (2005). A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology 183:133–43.
  • Javed A, Cohen B, Detyniecki K, et al. (2015). Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: an extended follow-up. Seizure 29:34–40.
  • Kawano T, Eguchi S, Iwata H, et al. (2016). Pregabalin can prevent, but not treat, cognitive dysfunction following abdominal surgery in aged rats. Life Sci 148:211–9.
  • Kenney JW, Gould TJ. (2008). Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol 38:101–21.
  • Klinkenberg I, Blokland A. (2010). The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev 34:1307–50.
  • Korczyn AD, Schachter SC, Brodie MJ, et al. (2013). Epilepsy, cognition, and neuropsychiatry (Epilepsy, brain, and mind, part 2). Epilepsy Behav 28:283–302.
  • Li Y, Pan K, Chen L, et al. (2016). Deferoxamine regulates neuroinflammation and iron homeostasis in a mouse model of postoperative cognitive dysfunction. J Neuroinflammation 13:268.
  • Lotarski SM, Donevan S, El-Kattan A, et al. (2011). Anxiolytic-like activity of pregabalin in the Vogel conflict test in α2δ-1 (R217A) and α2δ-2 (R279A) mouse mutants. J Pharmacol Exp Ther 338:615–21.
  • Mititelu-Tartau L, Ochiuz L, Lupusoru CE, et al. (2015). The effects of pregabalin on psycho-motor abilities and cognitive processes in mice. Rev Med Chir Soc Med Nat Iasi 119:185–92.
  • Mula M, Trimble MR. (2009). Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs 23:121–37.
  • Myhrer T. (2003). Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Brain Res Rev 41:268–87.
  • Navarrete F, Pérez-Ortiz JM, Manzanares J. (2012). Pregabalin- and topiramate-mediated regulation of cognitive and motor impulsivity in DBA/2 mice. Br J Pharmacol 167:183–95.
  • Patil SS, Sunyer B, Höger H, Lubec G. (2009). Evaluation of spatial memory of C57BL/6J and CD1 mice in the Barnes maze, the Multiple T-maze and in the Morris water maze. Behav Brain Res 198:58–68.
  • Paul CM, Magda G, Abel S. (2009). Spatial memory: theoretical basis and comparative review on experimental methods in rodents. Behav Brain Res 203:151–64.
  • Puzzo D, Lee L, Palmeri A, et al. (2014). Behavioral assays with mouse models of Alzheimer’s disease: practical considerations and guidelines. Biochem Pharmacol 88:450–67.
  • Read CL, Stephen LJ, Stolarek IH, et al. (1998). Cognitive effects of anticonvulsant monotherapy in elderly patients: a placebo-controlled study. Seizure 7:159–62.
  • Sałat K, Cios A, Wyska E, et al. (2014a). Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl] dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. Pharmacol Biochem Behav 122:173–81.
  • Sałat K, Gdula-Argasińska J, Malikowska N, et al. (2016). Effect of pregabalin on contextual memory deficits and inflammatory state-related protein expression in streptozotocin-induced diabetic mice. Naunyn Schmiedebergs Arch Pharmacol 389:613–23.
  • Sałat K, Jakubowska A, Kulig K. (2015a). Cebranopadol: a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors. Expert Opin Investig Drugs 24:837–44.
  • Sałat K, Kowalczyk P, Gryzło B, et al. (2014b). New investigational drugs for the treatment of neuropathic pain. Expert Opin Investig Drugs 23:1093–104.
  • Sałat K, Podkowa A, Kowalczyk P, et al. (2015b). Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression. Pharmacol Rep 67:465–72.
  • Sałat K, Podkowa A, Mogilski S, et al. (2015c). The effect of GABA transporter 1 (GAT1) inhibitor, tiagabine, on scopolamine-induced memory impairments in mice. Pharmacol Rep 67:1155–62.
  • Sałat K, Witalis J, Zadrożna M, et al. (2015d). 3-[4(3-Trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one and pregabalin attenuate tactile allodynia in the mouse model of chronic constriction injury. Toxicol Mech Methods 25:514–23.
  • Salinsky M, Storzbach D, Munoz S. (2010). Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. Neurology 74:755–61.
  • Samarasekera SR, Helmstaedter C, Reuber M. (2015). Cognitive impairment in adults with epilepsy: The relationship between subjective and objective assessments of cognition. Epilepsy Behav 52:9–13.
  • Sharma S, Rakoczy S, Brown-Borg H. (2010). Assessment of spatial memory in mice. Life Sci 87:521–36.
  • Siok CJ, Taylor CP, Hajós M. (2009). Anxiolytic profile of pregabalin on elicited hippocampal theta oscillation. Neuropharmacology 56:379–85.
  • Toth C. (2014). Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf 5:38–56.
  • Tsai ML, Hung KL, Tsan YY, Tung WT. (2015). Long-term neurocognitive outcome and auditory event-related potentials after complex febrile seizures in children. Epilepsy Behav 47:55–60.
  • Valente MM, Bortolotto V, Cuccurazzu B, et al. (2012). α2δ ligands act as positive modulators of adult hippocampal neurogenesis andprevent depression-like behavior induced by chronic restraint stress. Mol Pharmacol 82:271–80.
  • Witt JA, Elger CE, Helmstaedter C. (2015). Adverse cognitive effects of antiepileptic pharmacotherapy: each additional drug matters. Eur Neuropsychopharmacol 25:1954–9.
  • Wolf DC, Bueno-Júnior LS, Lopes-Aguiar C, et al. (2016). The frequency of spontaneous seizures in rats correlates with alterations in sensorimotor gating, spatial working memory, and parvalbumin expression throughout limbic regions. Neuroscience 312:86–98.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.